Skip to main content

Table 1 Baseline patient characteristics

From: A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]

Characteristic

Placebo

Etoricoxib 90 mg

Naproxen 1000 mg

 

(N = 357)

(N = 353)

(N = 181)

% women

82

81

82

Mean age [yrs] (SD)

52 (12)

53 (12)

52 (12)

Mean duration of rheumatoid arthritis [yrs] (SD)

9 (8)

8 (8)

8 (8)

% rheumatoid factor-positive

83

85

87

% in ARA functional class:

   

   I

27

31

27

   II

56

53

58

   III

17

16

16

% taking rheumatoid arthritis medications:

   

   Corticosteroids

57

54

59

   Disease modifying antirheumatic drugs

83

83

81

   Methotrexate

59

55

62

Mean patient global assessment of disease activity (100 mm visual analog scale) (SD)

65 (19)

66 (20)

65 (19)

Mean investigator global assessment of disease activity (0 to 4 scale) (SD)

2.7 (0.6)

2.7 (0.7)

2.7 (0.6)

Mean number of tender joints (of 68) (SD)

29 (15)

29 (15)

28 (15)

Mean number of swollen joints (of 66) (SD)

19 (12)

19 (13)

18 (12)

  1. Higher score corresponds to greater disease activity.